This chemical is primarily utilized in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It serves as a linker-payload component, where the Gly3-VC segment acts as a protease-cleavable linker, and MMAE is a potent cytotoxic agent. The PAB (p-aminobenzyl) group facilitates self-immolative release of MMAE upon linker cleavage. This structure enables precise delivery of the cytotoxic drug to cancer cells, minimizing damage to healthy tissues. It is commonly used in research and pharmaceutical development to create ADCs that target specific cancer biomarkers, enhancing the efficacy and safety of cancer treatments.